Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Note to self: Listen to Rolontis CC on Fri, June 29th

Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)

Business WireJune 25, 2018
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday, June 29th at 8:30 a.m. EDT/5:30 a.m. PDT to discuss the ROLONTIS Phase 3 ADVANCE study data being presented at Multinational Association of Supportive Care in Cancer (MASCC) 2018 annual meeting. The call will feature a presentation from ADVANCE study lead investigator, Lee S. Schwartzberg, M.D., FACP Professor of Medicine and Division Chief, Hematology Oncology, The University of Tennessee Health Science Center, and Executive Director, UT/West Cancer Center.

Conference Call Details
Friday, June 29, 2018 @ 8:30 a.m. Eastern/5:30 a.m. Pacific
Domestic: [phone], Conference ID# 6798817
International: [phone], Conference ID# 6798817
The conference call will also be webcast live. To access the webcast and additional documents related to the call, please visit the Investor Relations page of the Spectrum Pharmaceutical website at investor.sppirx.com/events-and-presentations.
For interested individuals unable to join the call, a webcast replay will be available online from June 29, 2018, @ 11:30 a.m. ET/8:30 a.m. PT through July 6, 2018 until 11:30 a.m. ET/8:30 a.m. PT.

Well, after re-listening to last September's CC on pozi from WCLC last September and all the great tidbits of NEW info we got on pozi, I'm hoping for something similar and they squeeze out some new info regarding Rolontis during this CC. Noteworthy is that it will be led by the lead investigator, Lee S. Schwartzberg, M.D., FACP Professor of Medicine and Division Chief, Hematology Oncology, The University of Tennessee, who should carry some scientific weight in discussing Rolontis. Note the anomaly in this PR. SPPI always lets us know 5 business days in advance when they are presenting, in this case, it's only 4 business days prior to the CC. Somehow I find that interesting.

ps. Having said all that, it looks like I won't be able to hear the CC till later that day or on the weekend. Nevertheless, I'll know if anything new was discussed, in all likely-hood, by seing what's going on with the share price.